EMCURE PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of EMCURE PHARMACEUTICALS have increased by 18.59% YoY .
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has increased by 35.60 % YoY. |
||
EMCURE PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 544210|NSE : EMCURE]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹7,896 Cr | ₹6,658 Cr | ₹5,986 Cr | ₹5,855 Cr | ₹6,056 Cr |
| Expenses | ₹6,427 Cr | ₹5,429 Cr | ₹4,805 Cr | ₹4,525 Cr | ₹4,824 Cr |
| Operating Profit (Excl OI) | ₹1,469 Cr | ₹1,230 Cr | ₹1,181 Cr | ₹1,330 Cr | ₹1,232 Cr |
| Other Income | ₹73 Cr | ₹57 Cr | ₹46 Cr | ₹63 Cr | ₹35 Cr |
| Interest | ₹176 Cr | ₹237 Cr | ₹214 Cr | ₹176 Cr | ₹198 Cr |
| Depreciation | ₹384 Cr | ₹312 Cr | ₹260 Cr | ₹245 Cr | ₹323 Cr |
| Profit Before Tax | ₹971 Cr | ₹727 Cr | ₹747 Cr | ₹973 Cr | ₹657 Cr |
| Profit After Tax | ₹707 Cr | ₹528 Cr | ₹562 Cr | ₹703 Cr | ₹419 Cr |
| Consolidated Net Profit | ₹681 Cr | ₹498 Cr | ₹532 Cr | ₹662 Cr | ₹392 Cr |
| Earnings Per Share (Rs) | ₹48.76 | ₹35.96 | ₹27.50 | ₹29.42 | ₹36.62 |
| PAT Margin (%) | 10.02 | 8.82 | 7.77 | 9.21 | 11.75 |
| ROE(%) | 20.09 | 19.19 | 19.45 | 25.21 | 33.19 |
| ROCE(%) | 25.25 | 22.49 | 19.87 | 21.97 | 26.56 |
| Total Debt/Equity(x) | 0.24 | 0.17 | 0.71 | 0.88 | 1.05 |
Key Financials |
||
| Market Cap | : | ₹ 44,314.9 Cr |
| Revenue (TTM) | : | ₹ 10,234.1 Cr |
| Net Profit(TTM) | : | ₹ 1,092.7 Cr |
| EPS (TTM) | : | ₹ 57.6 |
| P/E (TTM) | : | 40.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| EMCURE PHARMACEUTICALS | 0.6% | 32.3% | 69.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 7.3% | 7.7% |
| DIVIS LABORATORIES | -3.3% | 21.8% | 68.7% |
| TORRENT PHARMACEUTICALS | -1.7% | 1.9% | 22.1% |
| CIPLA | 0.7% | 6.7% | -9.4% |
| DR REDDYS LABORATORIES | 0.7% | 12.4% | 12.4% |
| MANKIND PHARMA | 0.2% | 17.2% | 15.5% |
| LUPIN | -2.2% | 0.8% | -4.8% |
| ZYDUS LIFESCIENCES | -0.9% | 7.4% | 27.4% |
EMCURE PHARMACEUTICALS Revenues
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 18.59 % |
| 5 Yr CAGR | 6.86 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,896 Cr | 18.59 | |
| Mar2025 | ₹6,658 Cr | 11.23 | |
| Mar2024 | ₹5,986 Cr | 2.23 | |
| Mar2023 | ₹5,855 Cr | -3.32 | |
| Mar2022 | ₹6,056 Cr | - | |
EMCURE PHARMACEUTICALS Operating Profit
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 19.45 % |
| 5 Yr CAGR | 4.49 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,469 Cr | 19.45 | |
| Mar2025 | ₹1,230 Cr | 4.11 | |
| Mar2024 | ₹1,181 Cr | -11.18 | |
| Mar2023 | ₹1,330 Cr | 7.95 | |
| Mar2022 | ₹1,232 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 0.70 % |
| 5 Yr CAGR | -2.21 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 18.6% | 0.70 | |
| Mar2025 | 18.47% | -6.39 | |
| Mar2024 | 19.73% | -13.12 | |
| Mar2023 | 22.71% | 11.65 | |
| Mar2022 | 20.34% | - | |
EMCURE PHARMACEUTICALS Profit After Tax
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 36.76 % |
| 5 Yr CAGR | 14.81 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹681 Cr | 36.76 | |
| Mar2025 | ₹498 Cr | -6.36 | |
| Mar2024 | ₹532 Cr | -19.66 | |
| Mar2023 | ₹662 Cr | 68.87 | |
| Mar2022 | ₹392 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 13.61 % |
| 5 Yr CAGR | -3.90 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.02 % | 13.61 | |
| Mar2025 | 8.82 % | 13.51 | |
| Mar2024 | 7.77 % | -15.64 | |
| Mar2023 | 9.21 % | -21.62 | |
| Mar2022 | 11.75 % | - | |
EMCURE PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 35.60 % |
| 5 Yr CAGR | 7.42 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹49 | 35.60 | |
| Mar2025 | ₹36 | 30.76 | |
| Mar2024 | ₹28 | -6.53 | |
| Mar2023 | ₹29 | -19.66 | |
| Mar2022 | ₹37 | - | |
EMCURE PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 544210|NSE : EMCURE]
| Y-o-Y | 12.27 % |
| 5 Yr CAGR | -1.26 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 25.25% | 12.27 | |
| Mar2025 | 22.49% | 13.19 | |
| Mar2024 | 19.87% | -9.56 | |
| Mar2023 | 21.97% | -17.28 | |
| Mar2022 | 26.56% | - | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,336.1 |
| Current MarketCap | : | ₹ 44,314.9 Cr |
| Updated EOD on | : | Nov 18,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | 0.6% |
32.3% |
69.4% |
| SENSEX | 0.2% |
9.8% |
-2.9% |
EMCURE PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 500 | -0.5% | 6.2% | -1% |
| BSE HEALTHCARE | -0.6% | 9.1% | 18.2% |
| BSE 1000 | -0.6% | 5.6% | -0.5% |
| BSE 250 SMALLCAP INDEX | -0.9% | 0.1% | 0.9% |
| BSE 400 MIDSMALLCAP INDEX | -0.9% | 2.1% | 0% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -0.6% | 6.1% | -0.9% |
| NIFTY500 HEALTHCARE INDEX | -0.7% | 10.1% | 18.2% |
| NIFTY500 MULTICAP 50:25:25 | -0.7% | 4.9% | 0.3% |
| NIFTY TOTAL MARKET | -0.7% | 5.8% | -0.5% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.7% | 3.8% | 0.8% |
You may also like the below Video Courses
FAQ about EMCURE PHARMACEUTICALS Financials
How the annual revenues of EMCURE PHARMACEUTICALS have changed ?
The Revenues of EMCURE PHARMACEUTICALS have increased by 18.59% YoY .
How the Earnings per Share (EPS) of EMCURE PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of EMCURE PHARMACEUTICALS has increased by 35.60 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs